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Cell therapies are emerging as a new therapeutic frontier for the treatment of ischemic
disease. However, femoral occlusions can be challenging environments for effective
therapeutic cell delivery. In this study, cell-engineered hybrid scaffolds are implanted
around the occluded femoral artery and the therapeutic benefit through the formation
of new collateral arteries is investigated. First, it is reported the fabrication of different
hybrid “hard-soft” 3D channel-shaped scaffolds comprising either poly(ε-caprolactone)
(PCL) or polylactic-co-glycolic acid (PLGA) and electro-spun of gelatin (GL) nanofibers.
Both PCL-GL and PLGA-GL scaffolds show anisotropic characteristics in mechanical
tests and PLGA displays a greater rigidity and faster degradability in wet conditions. The
resulting constructs are engineered using human adventitial pericytes (APCs) and both
exhibit excellent biocompatibility. The 3D environment also induces expressional changes
in APCs, conferring a more pronounced proangiogenic secretory profile. Bioprinting
of alginate-pluronic gel (AG/PL), containing APCs and endothelial cells, completes the
hybrid scaffold providing accurate spatial organization of the delivered cells. The scaffolds
implantation around the mice occluded femoral artery shows that bioengineered PLGA
hybrid scaffold outperforms the PCL counterpart accelerating limb blood flow recovery
through the formation arterioles with diameters >50µm, demonstrating the therapeutic
potential in stimulating reparative angiogenesis.
Keywords: tissue engineering, angiogenesis, adventitial pericytes, hybrid scaffold, biomaterials, bioprinting,
electrospinning
INTRODUCTION
Acute limb ischemia is the sudden loss of limb perfusion and is typically caused by an
occluding embolus, in situ formation of a thrombus, trauma, or dissection of a peripheral
artery. Chronic total occlusions of the femoral artery and implanted bypass grafts are common
in patients with symptomatic peripheral artery disease (PAD). It is estimated more than
200 million people worldwide are affected by PAD (1). Approximately 12–20% of people
over the age of 60 develop PAD with many developing critical limb ischemia (CLI), which
is associated with a poor quality of life and a high risk of amputation and death (2).
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Artery occlusion represents a dramatic event that threatens
limb viability and requires urgent evaluation and intervention
(3). The early stage of the pathology is usually treated with
pharmacological administration, whilst more acute forms of PAD
are treated with surgical intervention, via insertion of hydrophilic
wires to dissect through the intima or the media layers of
the artery (4, 5). However, surgical treatments are subjected to
durability issues related to the progression of the underlying
pathology and the need for repetitive interventions (6, 7). In
addition, in the most severe cases of CLI, patients are not suitable
for surgical revascularization due to multiple occlusions and lack
of autologous vessel replacement (8).
Approaches based on cell and gene therapy are in
development to promote vascular repair and tissue reperfusion,
stimulating reparative angiogenesis. Several studies have
demonstrated that the transplanted cells performed their
therapeutic action by a number of mechanisms including,
direct incorporation into the host tissue, (9) activation and
recruitment of resident stem cells, (10, 11) and by the release of
pro-angiogenic factors, such as growth factors and micro-RNAs,
able to activate the re-vascularization process (12–14). In the last
few decades, cell-based therapies have led to several promising
pre-clinical studies (10, 12, 15) and ultimately, clinical trials using
injected bone marrow-derived and peripheral blood-derived
hematopoietic cells have shown initial evidence of safety and
therapeutic efficacy (7, 16). Despite the promising results, the low
efficiency of cell retention in the ischemic area with a significant
reduction of stem cells a short time after the injection (17, 18)
and consequent reduction of therapeutic action represent the
main weaknesses of this approach. Moreover, injected stem cells
are prone to accumulation in tissue sinks, such as the lungs, liver
and spleen (19).
Many researchers are now focusing on scaffold-based tissue
engineering approaches to develop systems to achieve optimal
delivery of the cell product to the arterial occlusion. Pericytes,
EPCs and mesenchymal stem cells (MSCs) have shown the
ability to encourage neovascularization when encapsulated in
alginate or arginine-glycine-aspartic acid conjugated alginate
micro-particles (13, 20–22). Positive outcomes in ischemic
tissue of myocardial infarction were also shown by the use
of injectable hydrogels, such as polyethylene-glycol (PEG),
fibrin glue, chitosan hydrogel, and dextran-hyaluronic acid
hydrogel when combined with BM-derived stem cells and MSCs
(23–26). However, approaches involving a large number of
synthetic microparticle-bound cells need to achieve a minimum
beneficial effect that can disrupt the ischemic region, and
lead to adverse clinical outcomes. Moreover, the inability
to reproduce a supportive microenvironment with relevant
mechanical properties limits the potential for hydrogel-based
delivery systems.
Alternative methodologies use “hard” scaffolds as cell carriers,
with the advantage of selecting the appropriate design of the
structure according to the specific application. Indeed, the
scaffold’s material should attempt to match the topographic,
mechanical, and bioresorption/remodeling features of the host
tissue in order to stimulate the endogenous healing response.
This approach offers the potential benefits of stimulating
vasculogenesis both by delivering cells and by scaffold action
directly (27, 28). Several natural and synthetic polymers have
been explored and among those polycaprolactone (PCL) has
been widely used. PCL nanofibers conjugated with fibronectin,
and PCL 3D printed structures functionalized with gelatin
(GL) nanofibers have been used to deliver MSCs (29) and
adventitial pericytes (30) to infarcted myocardium and ischemic
limb, respectively, to stimulate revascularization. Despite the
increasing number of studies focused on using engineered
scaffolds to treat ischemic tissues by stimulating spontaneous
angiogenesis, the dominant mechanism of action is still
largely unknown.
In this study, we show hybrid hard-soft scaffolds, comprised
of microfabricated polymeric scaffolds with bioprinted hydrogel
seeded with vascular cells, had beneficial pro-angiogenic effects
in a murine model of LI. The novel hybrid scaffold, consisting
of a 3D printed synthetic polymer [PCL or polylactic-co-glycolic
acid (PLGA)] covered by a layer of electrospun GL nanofibers,
were fabricated to recapitulate a rudimentary morphology and
mechanical environment of the extracellular matrix (ECM)
surrounding the femoral artery. In addition, the topography of
the scaffold, enhanced by the cell-laden bioprinted gel, provided
preferential growth direction for the seeded cells. Adventitial
pericytes (APCs) isolated from saphenous veins were selected
to functionalize the scaffold due to their ability to promote
neovascularization or cell recruitment by secretion of paracrine
factors (10, 14, 31). The scaffold was further functionalized
with HUVECs to increase the therapeutic effect. Significantly,
the cellularized hybrid scaffolds were highly biocompatible and
promoted in vitro pro-angiogenic responses by the cells, with
increased expression of VEGF, ANGPT-1 and FGF observed.
The in vivo efficacy of this approach was investigated using a
mouse model of LI, with the fabricated hybrid scaffolds placed
around the occluded femoral artery. Here, the bioengineered
PLGA hybrid scaffold outperformed the PCL counterpart by
accelerating limb blood flow recovery and increasing the number
of functional arterioles which supported scaffold resorption rate
over matched mechanical properties as the dominate indicator of
scaffold performance.
MATERIALS AND METHODS
Cell Lines and Cultures
Studies using human cells were covered by Research Ethics
Committee approvals (06/Q2001/197 and 11/2009) and
complied with the principles stated in the 1964 Declaration of
Helsinki and later amendments. All the subjects gave informed
written consent for the experimental use of donated material
(Supplementary Table 1). APCs were obtained from saphenous
vein leftovers using immunomagnetic beads sorting and an
expansion protocol described previously (31). The antigenic
phenotype was evaluated by flow cytometry using a FACS Canto
II flow cytometer and FACS Diva software (BD Biosciences).
A combination of the following antibodies was employed:
anti-CD44 (eBioscience), anti-CD-105 (Life Technologies) and
anti-CD90 (BD biosciences). The purity of the cell preparation
was confirmed, with >95% cells expressing the above markers.
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All in vitro and in vivo experiments were set up with APCs
at passage 6. Commercially available human umbilical vein
endothelial cells (HUVECs, Lonza cat#: CC-2517, lot:460587)
were cultured at 37◦C, 20% O2, 5% CO2 in complete Endothelial
growth medium-2 (EGM-2, PromoCell) and used between
passages 5 and 7.
Materials and Reagents
PCL (Mn average 80,000), Pluronic R© F-127 (PL), Sodium
Alginate (AG) and gelatin from porcine skin (GL) were
purchased from Sigma-Aldrich. 50:50 PLGA (Inherent Viscosity
= 0.55–075 dL/g) was purchased from DURECT corporation
(Cupertino, US). Gelatin crosslinking agent γ-glycidoxypropyl-
trimethoxysilane (GPTMS) from Sigma-Aldrich. Endothelial
basal medium-2 (EBM-2, cat# C-22211, Promocell) was used
for in vitro specific assays, while complete EGM-2, consisting
of EBM-2 supplemented with SupplementPack (cat#: C-39211,
PromoCell), was used to culture APCs and HUVECs. Fetal
bovine serum (FBS) was obtained from Hyclone (UT, USA).
Phosphate buffer saline (PBS), penicillin and streptomycin




The hybrid scaffold was fabricated using different techniques
which followed a bottom-up approach aiming at mimicking
the hierarchical organization of the natural extracellular
matrix (ECM).
The fabrication of the scaffold followed the procedure
reported in the previous work (30). In brief, the nanoscale
structure of natural GL polymer was overlapped to a pre-existing
matrix of synthetic material. In this study, PCL and PLGA were
used as a synthetic backbone to generate two types of scaffolds
with different physical properties. The synthetic matrices were
manufactured with a customized piston-driven 3D printing
system (MandleMax3, Maker’s Tool Works, US) (Figure 1A),
which allowed the extrusion of PCL and PLGA through a layer-
by-layer deposition. PCL 10% (w v−1), and PLGA 15% (w v−1)
were dissolved in chloroform, loaded in a glass syringe with a
32 gauge needle and extruded to generate a channel pattern. The
channel pattern consisted of the deposition of a first layer with
the shape of a grid, to avoid the collapse of the structure, followed
by six layers of parallel lines, to form the walls of the channels
(Figure 1B). A solution of Hydrolene R© LTF/K (Ecopol S.p.A.,
Italy) [4% (w v−1) in distilled water] was used as support material
during the extrusion of the polymeric solutions. The composite
scaffolds were completed by the electrospinning of GL nanofibers
on top of the synthetic structures to improve the biomimetic
and adhesive features of the scaffold (Figure 1C). After dissolving
porcine GL in acetic acid-water solution (ratio of 60:40) at the
concentration of 15% (w v−1), the crosslinking agent GPTMSwas
added at the concentration of 3% (v v−1) and stirred for 1 h before
the use of the solution. The GL solution was then electrospun
using an Electrospinning Station (Nadetech R©, Navarra Spain),
setting parameters to the following values: 25 kV (Voltage), 20 cm
(distance from the collector) and 0.2ml h−1 (flow rate).
Mechanical Property of the Scaffold
Mechanical characterization of the scaffold was performed using
Instron 3343 (©Illinois Tool Works Inc., US). PCL- and PLGA-
based scaffolds, fabricated with the dimension of 12 × 12mm
wide specifically for this test, were clamped with pneumatic
grips with an initial displacement of 5mm. The uniaxial test
machine was set with a steady deformation speed of [(0.006∗
l0) min
−1]. Polymeric structures were tested in both axial (x)
and longitudinal direction (y). In addition, mechanical properties
were further evaluated in relation to the degradation rate. PCL-
and PLGA-based scaffolds were conditioned with EBM-2 and
incubated at 37◦C, mimicking the cell culture environment, and
uniaxial tests were performed at specific time-points [0, 2, 4, 7, 10
days (n= 3 each time-point)].
Scaffold Cellularization
APC Seeding on Scaffold
PCL- and PLGA-based scaffolds of the dimension of 6 × 6mm
wide was prepared following an established sterilization protocol.
Scaffolds underwent sequential washes with 70% ethanol and
PBS and then exposed to UV light for 15min. The polymeric
structures were then washed with PBS and conditioned with
EGM-2 culture medium for 1 h. APCs, at passage 6, were then
seeded at a density of 6,000 cell cm−2 onto scaffolds and cultured
for 5 days, with medium changed on day 3.
Functional Assays
The cell behavior after seeding and culturing on different
polymeric materials was assessed by evaluating density, viability,
and proliferation. APCs were labeled with the fluorescent
marker 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine
perchlorate (Dil) (Cell-TrackerTM CM-DiI, Molecular Probes,
Leiden, Netherlands) and seeded onto the scaffold as described
above. After 5 days of incubation, cellularized scaffolds were
washed with PBS, fixed with PFA 4%, then counterstained with
DAPI, mounted with antifade mounting medium.
The viability of the APCs seeded onto PCL- and PLGA-based
scaffold was assessed using the viability/cytotoxicity assay kit
(Biotium Inc, US). Five days after seeding, the culture medium
was removed, the scaffold washed with PBS and incubated for
30min with a solution of Calcein [1:2000], EthD-III [1:500] and
Hoechst [1:100] in serum-free medium at 37◦C, 5% CO2. Viable
cells were identified using fluorescence microscopy. The ability
of cells to proliferate once seeded onto scaffolds was evaluated
by Click-iT R© EdU Assay (Life Technologies, UK). Fluorescent
images of the scaffolds were obtained using a Zeiss Fluorescent
Microscope (Zeiss Axio observer Z1, Zeiss) and number of cells
quantified using Image-Pro Plus software. All the functional
assays in this study were performed on three cell lines, in
technical triplicates.
Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR)
Total RNA was isolated from APC-bioengineered PCL and
PLGA scaffolds by a standardized phenol-chloroform protocol
combining QIAzol lysis and miRNeasy mini kit (QIAGEN,
Germany), following manufacturer’s instructions.
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FIGURE 1 | Schematic description of scaffold fabrication process. (A) Image of the customized piston-driven 3D printing system (MandleMax3, Maker’s Tool Works,
US); (B) 3D render of the designed pattern for channels structures of poly(ε-caprolactone) (PCL) and polylactic-co-glycolic acid (PLGA), highlighting the piling of
various layers and the directions (x) and (y); (C) Schematic 3D representation showing the electrospinning of the gelatin (GL) nanofibers on the upper surface of the
synthetic backbone of the composite scaffold (PCL or PLGA).
Briefly, PCL- and PLGA-based scaffolds seeded with APCs
for 5 days were washed once in PBS to remove non-adhered
cells. Scaffolds were then collected from the culture plate, lysed
in tubes with 1ml QIAzol l, and stored on ice. The tubes were
centrifuged to separate debris of polymeric structures and the
supernatant was transferred to clean tubes. Cell monolayers
seeded in culture petri dishes, used as control [hereafter referred
to as bi-dimensional (2D) counterparts], were washed with PBS,
and incubated with QIAzol; then, cell lysates were collected in
tubes. Scaffold derived debris were removed by centrifuging at
10,000 g, 3min, 4◦C before chloroform separation of organic and
inorganic phases. Chloroform was added to both cell lysates from
scaffolds (3D) and 2D counterparts, followed by centrifugation at
12,000× g for 15min at 4◦C.
Resulting total RNA was reverse-transcribed into single-
stranded cDNA using a High Capacity RNA-to-cDNA Kit (Life
Technologies, UK) (100 ng RNA), or using specific Taqman
microRNA assay primers with a TaqMan R© MicroRNA Reverse
Transcription Kit (10 ng) for the assessment of microRNA
expression (both from Life Technologies). Quantitative real-
time PCR (qPCR) of first-strand cDNA was performed using
TaqMan Fast Universal PCR Master Mix or SYBR Green
PCR (both from Life Technologies, UK) as appropriate into a
QuantStudio 6 Flex (Thermo Fisher Scientific). Targeted genes
include markers for apoptosis, angiogenesis, pericyte profile
and myofibroblast transformation: BAX (Hs00180269_m1),
BCL2 (Hs04986394_s1), PDGFRB (Hs01019589_m1),
ANG-1 (Hs00375822_m1), VEGFA (hs00900055_m1),
BACH1 (Hs00230917_m1), FGF (Hs01092738_m1)
(all of them TaqMan R© probes, Applied Biosystems);
ACTA2/SMA (QT00088102, Hs_ACTA2_1_SG), TGLN/SM22A
(QT00072247, Hs_TAGLN_1_SG), COL1A1 (QT00037793,
Hs_COL1A1_1_SG), MYOC (QT00068327, Hs_MYOC_1_SG),
and MYH11 (QT00069391, Hs_MYH11_1_SG) (all of
them. QuantiTect Primer Assay-QIAGEN for SYBR
Green applications).
MicroRNA profile preservation was additionally assessed
with specific miRNA assay probes has-miR-132-3p (assay no.
000457), hsa-miR-532-5p (assay no. 001518), and hsa-miR-210-
3p (assay no. 000512). miRNA expression was normalized to
U6 snRNA (assay no.001973) (all of them TaqMan R© probes,
Applied Biosystems).
Relative mRNA expression was calculated using the 2−11ct
method (Livackmethod) and expressed as fold-change compared
to 2D control counterparts. All experiments were performed on
three biological replicates and assessed in technical triplicates.
Enzyme-Linked Immunosorbent Assays (ELISA)
Cell conditioned media (CCM) from APC-bioengineered
scaffolds (3D) or 2D control counterparts was collected and
assayed for angiopoietin-1 (ANG-1) and vascular endothelial
growth factor-A (VEGFA) using specific sandwich ELISA
(DuoSet ELISA, R&D Systems). In brief, after 3 days in culture,
EGM-2 growing media was replaced with all control and
experimental conditions with fresh growth factor-depleted EBM-
2. Cells were kept for 48 h more at 37◦C, 5% CO2, 21% O2
and CCM were collected and centrifuged at 10,000 g, 3min, 4◦C
to remove cell debris. CCMs were kept at −80◦C until batch
analysis. Data are shown as fold change by comparing to 2D
control counterparts to assess for biological significance of our
findings and avoid the effect of donor heterogeneity.
Final Hybrid Scaffold Preparation
Hydrogel Preparation: Sodium Alginate/Pluronic
Based Gel
AG and PL solutions were produced following the protocol
described by Armstrong et al. (32). Briefly, the final hydrogel
working solution was produced by combining solutions of PL
and AG to achieve a final gel of 13% (w v−1) PL and 6% (w
v−1) AG in serum-free DMEM (Gibco Life TechnologiesTM).
The gel was then crosslinked with CaCl2 to achieve higher
water resistance.
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Hydrogel Printing Characterization
Hydrogel printability and biocompatibility were further assessed
before the final assembly. The extrusion of the cell-laden hydrogel
was also performed with the piston-driven 3D printing system.
A pattern of 12 × 12mm grid was chosen to evaluate the
gel printability. Solutions of EBM-2 with CaCl2 at different
concentrations were used to assess the shape maintenance of the
structures after printing, followed by the analysis of cytotoxicity
effect of the crosslinking agent. Both APCs and HUVECs were
tested. The cell-laden gel solution of AG/PL gel, [13% (w v−1)
PL and 6% (w v−1)] with cells were loaded into a 1ml sterile
and disposable syringe, fixed to the bioprinter holder, with
subsequent hydrogel printing onto a sterile coverslip. For these
tests, cell concentration was fixed at 1 million·ml−1; while, for the
final scaffold, concentration was increased up to 4 million·ml−1.
The extruded structures were incubated with CaCl2-EBM-2
solutions (5, 10, 20, 30, 50, and 100mM) for 10min at 37◦C
and 5% CO2 for the first crosslinking phase. The gels were
washed with PBS and incubated a second time with 5mM CaCl2
solution at 37◦C and 5% CO2. After additional 24 h, the CaCal2-
medium was changed with complete EGM-2 and incubated for
24 h. At the end of this period, fluorescent images acquired with
Zeiss Fluorescent Microscope were used to evaluate the shape of
the extruded pattern and viability of cells was assessed using a
dedicated kit (Biotium Inc, US). Percentages of viable cells were
quantified with Image-Pro Plus.
Cell-Laden Gel Patterning
PCL-based and PLGA-based scaffolds coated with GL nanofibers
crosslinked with GPTMS were cellularized with APCs, as
described above. After a culture period of 5 days, scaffolds were
used as a substrate to extrude a patterned layer of the cell-
laden gel. Co-culture of APCs and HUVECs [1:4] was loaded in
AG/PL gel [13% (w v−1) PL and 6% (w v−1)] with a total cell
concentration of 4 million ml−1, gently mixed to homogenize
the solution and then transferred into a 5ml syringe with a 27
gauge needle for the bioprinting process. The cellularized scaffold
was quickly placed on the heated plate of the Bioprinter and
the extrusion was activated. The cell-laden gel was deposited
on the scaffold with the pattern of lines parallel to the (x)
direction of the scaffolds. At the end of the extrusion, the
scaffold was incubated with 100mM CaCl2-EBM-2 solution for
10min. Then, the solution was removed and 5mM solution of
CaCl2-EGM2 (supplemented with 1% penicillin/streptomycin)
was added. This established protocol was used to prepare hybrid




Experiments involving live animals were performed in
accordance with the Guide for the Care and Use of Laboratory
Animals (The Institute of Laboratory Animal Resources, 1996)
under British Home Office PPL 30/3373, after Ethical approval
from the University of Bristol. Data were reported according
to the ARRIVE guidelines. Male C57Bl/6J mice (8 weeks old;
Charles River, UK) underwent unilateral femoral artery ligation
under isoflurane anesthesia. The proximal and the distal end of
the femoral artery were occluded using 6-0 silk, and the portion
of the artery between the ligations was electro-coagulated. Group
size was calculated to detect a 20% difference in the primary
endpoint between groups with a = 0.05 and a power of 80%.
Mice were randomly assigned to five experimental groups
(n = 10 per group) described as follows: group I was given
no treatment (vehicle); group II was implanted with PCLGL
+ AG/PL without cells; group III with PLGA-GL + AG/PL
without cells; group IV with PCL-GL + AG/PL with cell; and
group V with PLGA-GL + AG/PL with cells. Scaffolds were
properly dimensioned in 3 × 3mm squares for the in vivo
application. During the implantation procedure, the scaffolds
were positioned between the ligations and wrapped around
the occluded femoral artery, with the PCL or PLGA in contact
with the artery and the gel with or without cells exposed to the
perivascular tissues. After being given Vetergesic analgesia, the
animals were allowed to recover. The mice were given standard
chow and water ad libitum and inspected regularly for any
change in clinical signs.
The primary endpoints were blood flow recovery and vascular
density. The ischemic foot was sequentially monitored by color
laser Doppler at 0, 3, 7, 14, and 21 days after induction
of ischemia (33). The recovery was assessed by comparing
the ratio of flow in the ischemic and contralateral legs.
Mice were killed under terminal anesthesia on day 21. The
adductor muscles and the perivascular area (including the
femoral artery and scaffold) were excised intact, fixed with
PFA (4% w v−1 in PBS) overnight, and then embedded in
optimal cutting temperature (OCT) medium. Samples were
sectioned at a thickness of 5–7µm using a Cryotome (LEICA
RM2235, Germany).
Immunohistochemistry Staining
For analysis of vascularization, sections of adductor muscle
and the perivascular area were incubated overnight at 4◦C with
primary α-SMA-Cy3 (c6198, Sigma, UK), to identify VSMCs,
and Alexa 488-conjugated isolectin B4 (Life Technologies,
UK) to identify ECs. Streptavidin-Alexa 488 secondary
antibody. Sections were counterstained with DAPI (30 nM),
to identify nuclei, and coverslips mounted using antifade
mounting medium.
Statistical Analysis
Continuous variables distribution was assessed by Kolmogorov–
Smirnov Z normality test and Shapiro Wilk test and are shown
as mean ± standard error of the mean (SEM) or standard
deviation (SD) or as median (IQR), depending on the sample
distribution. Continuous variables normally distributed were
compared using the Student’s t-test (two-group comparison) or
one-way analysis of variance followed by Tukey PostHoc analysis
(ANOVA; for multiple group comparisons), as appropriate. Two-
way ANOVA analysis was used to compare the mean differences
between groups in the animal model (two categorical and one
continuous variable) followed by pair-wise comparison using
the Holm-Sidak method. Non-parametric tests, including the
Mann–Whitney U test or the Kruskal-Wallis test, were used for
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FIGURE 2 | Fabricated multi-material scaffold. (A) Representative image of channel structure; (B) Representative SEM picture of the composite scaffold formed by
gelatin (GL) nanofibers covering polylactic-co-glycolic acid (PLGA) cannels structure; (C) Representative SEM picture of the GL nanofibers.
data not normally distributed. A P-value < 0.05 was considered
statistically significant. Analyses were performed using GraphPad
Prism 8.0 statistical software.
RESULTS
Feasibility of Composite Polymeric
Scaffold Production
In order to elucidate the in vitro and in vivo responses to scaffold
biomaterials, which differ systematically inmechanical properties
and resorption rate, we compared two synthetic polymers, PCL
and PLGA. The hybrid hard-soft scaffolds were fabricated using
an adaption of a bottom-up approach with the aim being
to mimic the hierarchical organization of natural ECM (30).
In brief, the nanoscale structure of natural GL polymer was
overlapped on a pre-existing matrix of synthetic material. In this
study, PCL and PLGA were used as the synthetic backbone to
generate two types of scaffolds with different physical properties.
The synthetic matrices were manufactured using a customized
piston-driven 3D printing system (MandleMax3, Maker’s Tool
Works, US), which allowed the extrusion of PCL or PLGA via
a layer-by-layer deposition.
The customized piston-driven printing system (Figure 1A)
allowed the extrusion of PCL (10% w v−1) or PLGA (15%
w v−1) polymer solutions, following with high resolution the
designed pattern of the channel (Figure 1B). Assessment by
optical microscopy showed the full thickness of the scaffolds was
70± 10µm and line width was 121± 15µm for PCL and 127±
23µm for PLGA, respectively (Figure 1C).
The synthetic backbone of PCL or PLGA was then covered
by electrospinning GL nanofibers directly onto the surface
(Figure 2A). GL nanofibers were then crosslinked with GPTMS
3% (v v−1) to improve durability in wet conditions. The
successful assembling of the PCL-GL or PLGA-GLmulti-material
scaffolds was assessed by SEM (Figure 2B). The mat of GL
nanofibers was uniformly distributed and adherent to the upper
surface of the syntheticmaterials. Additionally, the GL nanofibers
were randomly oriented and had an average diameter of 90 ±
18 nm and a pore size 290± 18 nm (Figure 2C).
Material Composition Confers Different
Mechanical Properties to the Scaffolds
Mechanical tests were performed to evaluate the properties
of the different biomaterials, the effect of the geometry and
the response to incubation in wet conditions over time. The
data from mechanical testing are reported in Figure 3A and
Table 1. Scaffolds made of PCL had different values in the
axial direction (x) compared with the longitudinal direction (y),
namely higher values of Young’s modulus [(x): 5.37 ± 0.37
vs. (y): 0.91 ± 0.51 MPa, P < 0.001] and maximum stress
[(x): 0.43 ± 0.12 vs. (y): 0.09 ± 0.019 MPa, P < 0.01]. PLGA
scaffolds followed similar patterns for both Young’s modulus
[(x): 32.86 ± 8.9 vs. (y): 7.44 ± 1.14 MPa, P < 0.01] and
maximum stress [(x): 0.77 ± 0.16 vs. (y): 0.23 ± 0.07 MPa, P <
0.01]. These results indicate the two constructs have anisotropic
mechanical characteristics.
Comparing the PLGA and PCL structures, the former had
significantly higher values of Young’s modulus [(x): P < 0.01 and
(y): P < 0.001] and maximum stress (P < 0.05). Conversely, PCL
showed higher values of strain at maximum stress [(x): P < 0.05
and (x): P < 0.001] and strain at rupture (P < 0.01). This data
confirms the higher rigidity of the PLGA structure, as illustrated
by the stress-strain curves in Figure 3B.
We next assessed the changes in mechanical features during
incubation of the structure in EBM-2 for up to 10 days
(Figure 3C). PCL showed resistance to degradation, its properties
remaining steady until the end of the observational period. In
contrast, the PLGA structure showed fast degradation, resulting
in a drastic decrease of Young’s modulus, maximum stress and
strain at rupture from day 4 of incubation.
Scaffold Cellularization With APCs and
Biocompatibility Assessment
Having achieved a robust production protocol for the PCL-
GL and PLGA-GL composite scaffolds, we next performed
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FIGURE 3 | Mechanical characterization of the scaffolds. (A) Bar graphs summarize results of mechanical tests on poly(ε-caprolactone) (PCL) and
polylactic-co-glycolic acid (PLGA) structures namely: Young’s modulus, maximum stress, strain at maximum stress and strain at rupture. Values are means ± SD, N =
3 biological replicates, each one with 3 technical replicates. *P < 0.05, **P < 0.01, ***P < 0.001, vs. PCL-scaffold within same direction of testing [(x) or (y)]; ##P <
0.01, ###P < 0.001 vs. the (x) direction of the corresponding group (PCL or PLGA). (B) Stress–strain curves of synthetic structures (PCL and PLGA) in both
directions (x and y). (C) Graphs showing mechanical features of PCL and PLGA scaffolds at different timepoints.
cellularization through two stages. The first stage consisted of
APC seeding by pipette deposition onto the scaffold surface, and
the evaluation of the in vitro interaction of the cells with the
different biomaterials (Figures 4A,B). Cell monolayers seeded in
culture petri dishes were used as control [hereafter referred to as
bi-dimensional (2D) counterparts].
Five days after the seeding, cell density, viability and
proliferation were evaluated. Overall, the results of the assays
indicated good biocompatibility for both the PCL-GL and
PLGA-GL scaffolds. Fluorescent microscopy confirmed the
homogeneous growth of APCs on the scaffold surfaces, with PCL
scaffolds having more adherent cells (P < 0.05) (Figure 4C) than
PLGA scaffolds.
APC viability was high with both materials (90 ± 3% for
PLGA and 92 ± 2% for PCL scaffold) (Figure 4D). These data
were further validated at the molecular level by measuring the
mRNA expression of pro-apoptotic BAX and pro-survival BCL2
genes. The APC-bioengineered scaffolds showed a BAX/BCL2
ratio superior to 2D control counterparts, but the difference did
not reach statistical significance (PCL: 2.48± 0.58-fold change vs.
2D; PLGA: 1.47± 0.19-fold change vs. 2D). Cell proliferation was
observed on both PCL and PLGA-based scaffolds, with 61 ± 4%
and 56 ± 17% of cells showing Edu-positive nuclei, respectively
(Figure 4E). Despite a certain degree of directionality given by
the macro-domain of the polymeric scaffolds, APCs tended to
rearrange in random directions.
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PCL Ch-X 5.37 ± 0.40 0.43 ± 0.10 226.5 ± 98.5 230.7 ± 99
PCL Ch-Y 0.91 ± 0.51### 0.09 ± 0.019## 147.9 ± 22.3 148 ± 23.6
PLGA Ch-X 32.86 ± 8.9** 0.77 ± 0.16* 4.82 ± 2.3* 105.7 ± 70
PLGA Ch-Y 7.44 ± 1.14***,## 0.23 ± 0.07*,## 7.13 ± 1.35*** 40.4 ± 13**
Values are means ± SD, N = 3 biological replicates, each one with 3 technical replicates.
*P < 0.05,**P < 0.01, ***P < 0.001, vs. PCL-scaffold within same direction of testing
(Ch-X or Ch-Y); ##P < 0.01, ###P < 0.001 vs. the Ch-X direction of the corresponding
group (PCL or PLGA).
Culture in Scaffolds Modifies the
Expressional Profile of APCs
In a parallel experiment, we investigated if PCL-GL or
PLGA-GL scaffolds impair the characteristic antigenic and
proangiogenic profile of APC. After 5 days of culture on the
scaffolds, immunocytochemistry (ICC) was used to show APC
protein expression of PDGFR-β, NG2 and vimentin markers
(Figure 5A). Additionally, RNA was extracted and used to
analyze the transcriptional signature of APCs by qPCR, using 2D
control counterparts to calculate the relative mRNA expression.
PDGFRB, a marker shared by pericytes and VSMC, was reduced
in 3D conditions (PCL: 0.40 ± 0.16-fold change vs. 2D, P
< 0.05; PLGA: 0.39 ± 0.15-fold change vs. 2D, P < 0.05).
The mRNA levels of ACTA2/SMA (VSMC and myofibroblast
marker), TGLN/SM22A (an early marker of smooth muscle
differentiation), COL1A1 (mainly expressed by myofibroblasts
and active VSMC) and MYH11 (a major VSMC contractile
protein) were significantly down-regulated, thus suggesting the
3D environment affected the expression of genes that characterize
the functional transition of pericytes toward myo-fibroblastic
cells (Figures 5B,C). No differences were seen with respect to
the mRNA expression of transcription factorsGATA4, SOX2, and
NANOG, which we have previously shown to be associated with
the progenitor-like profile of human APCs (data not shown) (31).
Furthermore, previous studies have shown that APCs
express several angiogenesis-related microRNAs (miRs) and
transcription factors (34–36). The expression of miR132-3p
and miR210-3p was similar in APCs embedded in PCL
or PLGA compared to 2D control counterparts. However,
miR532-5p was found to be down-regulated in APCs under
3D conditions, showing a significant difference vs. 2D for
PLGA-embedded cells (P < 0.05) (Figure 5D). Expression of
BACH1, a transcription factor which is a negative regulator of
ANGPT1 and heme-oxygenase-1, was downregulated in APC
seeded on both polymers (PCL: 0.39 ± 0.03-fold change vs.
2D, P < 0.05; PLGA: 0.52 ± 0.13-fold change vs. 2D, P <
0.05) (Figure 5E). Interestingly, the three-dimensionality of the
scaffold was associated with an increased expression of the
arteriogenic factor FGF by APCs (PCL P < 0.001 vs. 2D and
PLGA P < 0.01 vs. 2D). Moreover, APCs showed an upregulation
of VEGFA mRNA in both PCL (3.92 ± 1.16-fold change, P <
0.05 vs. 2D) and PLGA scaffolds (3.85 ± 0.57-fold change, P
< 0.01 vs. 2D). However, ANGPT1 expression was significantly
downregulated in cells seeded on the 3D structures (PCL: 0.44 ±
0.04-fold change vs. 2D, P < 0.01; PLGA: 0.45 ± 0.1-fold change
vs. 2D, P < 0.01).
The expression of VEGFA and ANGPT1 were further verified
by assaying the APC-derived secretome (Figure 5F). VEGFA was
found to be up-regulated in both PCL (4.11 ± 0.53-fold change
vs. 2D, P < 0.01; or 6.54 ± 1.06-fold change vs. 2D) and PLGA
(5.07 ± 0.99-fold change vs. 2D, P < 0.01; or 7.33 ± 0.21-fold
change vs. 2D). As per the qPCR results, ANGPT1 levels were
reduced in PCL (0.36 ± 0.02-fold change vs. 2D, P < 0.01) but
not in PLGA (P = 0.441). Altogether, the data suggest that 3D
culture at this timepoint confers APCs with a pro-angiogenic
growth profile, where induction cues (FGF/VEGFA) prevail over
factors involved in stabilization (ANGPT1).
Characterization of Structure Fidelity of
Sodium Alginate-Pluronic Gel and
Evaluation of Cell Viability
Having evaluated the behavior of the APCs on the PCL-GL and
PLGA-GL scaffolds, the final assembly of the hybrid scaffold
consisted of the deposition of lines of gel, as described in
Figures 6A,B. In fact, data shown above and results from a
previous study (30), the polymeric scaffold itself did not ensure
an ordered alignment of the cells. The spatial organization of
the scaffolds was here enhanced by the deposition of gel with
a specific pattern. The pattern of the scaffold improved the
directionality of the cellularized structure (Figures 6C,D) aiming
at promoting cells encapsulation and growth in specific lines.
The hydrogel was formed by a solution of AG due to its high
biocompatibility and PL for its increased printability properties.
Moreover, PL has the function of sacrificial material, when it
is washed out it will generate bigger pores that improve cell
interaction properties. AG and PL solutions were produced
following the protocol described by Armstrong et al. (32). The
final assembly of the hybrid scaffolds consisted of bioprinting
the cell-laden gel to a specific pattern on the surface of the APC
bioengineered PCL- and PLGA-based structures. The AG/PL gel
was produced with a final concentration of 13% (w v−1) PL and
6% (w v−1) AG in serum-free DMEM.
Before incorporation into the final scaffold, the hydrogel
underwent further fine-tuning of its properties. First, to improve
the durability in wet conditions, the hydrogel was crosslinked
with CaCl2 at different concentrations (5, 10, 20, 30, 50, 100mM)
(Figures 6E–G). Gel grids (12 × 12mm) were bioprinted and,
after 5 days of incubation in a culture medium, the morphology
of the hydrogel structure was evaluated. Immunofluorescence
images showed that grids incubated with a concentration
of CaCl2 above 20mM had better structure fidelity and
maintained the bioprinted grid shape after 5 days of incubation
(Figures 6H,I).
Next, we evaluated the possible cytotoxic effect of the
crosslinking agent on cells loaded into the AG/PL gel.
The analysis of cell viability showed that both APCs and
HUVECs maintained viability (around 70%) through increasing
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FIGURE 4 | In vitro cellularization of scaffolds and functional assessment. (A,B) Schematic representation of the Hybrid scaffold preparation following the specific
steps: (A) step a: fabrication of the composite scaffold formed by poly(ε-caprolactone (PCL) or polylactic-co-glycolic acid (PLGA) and gelatin (GL) nanofibers, named,
respectively, PCL-GL and PLGA-GL; (B) step b: seeding with adventitial pericytes (APCs) and culturing for 5 days; (C) Bar graph of cell density and representative
fluorescent microscopy images of PCL and PLGA scaffolds seeded with APCs. Nuclei are stained with DAPI (blue) and cell bodies are labeled with Dil (red). (D) Bar
graph of cell viability and representative images of APCs: viable cells stained with calcein (green), dead cells with EthD-III (red) and all the nuclei with Hoechst (blue) for
assessment of cell viability. (E) Bar graph of cell proliferation and representative images of APCs on scaffolds [proliferating cells stained by EdU (pink) and not
proliferating ones with DAPI (blue)]. Values are means ± SD, N = 3 biological replicates, each one with 3 technical replicates. *P < 0.05, vs. PLGA-scaffold.
concentrations of CaCl2 (Figure 6J). We selected 100mM CaCl2
to use in subsequent studies, as this combined maintenance of
scaffold shape with low cytotoxicity.
Final Scaffold Cellularization: In vitro
Evaluation of the Final Gel-Patterned
Hybrid Scaffold Containing APCs and
HUVECs Co-culture
The final assembly of the scaffold was performed using an
AG/PL bioprinting pattern of a set of parallel lines along the
(x) direction of the scaffolds to confer preferential direction
of cell growth. The co-culture of APCs-HUVECs was used in
the final hybrid scaffold to improve APCs action in promoting
angiogenesis once implanted in vivo. The AG/PL gel was
bioprinted with co-culture of APCs and HUVECs [at 1:4
ratio], with a total concentration of 4 million ml−1 cells.
The shape gel lines were maintained for 5 days incubation
(Figure 6K). From the observation of SEM images, the average
line width of the extruded gel was 510 ± 33µm and
the adhesion of the AG/PL gel was confirmed (Figure 6L).
Figures 6M,N illustrate higher magnification images of the
complete hybrid scaffolds (PCL-GL + AG/PL and PLGA-GL
+ AG/PL), confirming the high preservation of the bioprinted
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FIGURE 5 | Effect of 3D culture on poly(ε-caprolactone) with gelatin nanofibers (PCL-GL) and polylactic-co-glycolic acid with gelatin nanofibers (PLGA-GL) on APCs.
Bar graphs show the average of 3 biological replicates comparing the 3D conditions to the 2D monolayer culture on petri dish. (A) Representative fluorescence
images of specific phenotype markers (NG2, PDGFR-β and Vimentin) in APCs seeded, respectively, on PCL- and PLGA-based scaffolds; images showed that all the
cells were positive for the indicated markers. (B,C) Expression of differentiation (PDGFRB, ACTA2/SMA, TGLN/SM22A, COL1A1, and MYH11) molecules. (D)
Expression of angiogenic miRs: miR132, miR210-3p, and miR532. (E) BACH1, FGF, VEGFA, and ANG-1 molecules. (F) Bar graph shows the secreted of VEGFA and
ANG-1. *p < 0.05, **p < 0.01, and ***p < 0.001 vs. 2D. Values are means ± SE, N = 3 biological replicates, each one with 3 technical replicates. ****p < 0.0001.
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FIGURE 6 | Effect of cross-linking on structure fidelity and cell viability. (A–D) Schematic representation of the final hybrid scaffold preparation following the specific
steps (A,B were already described in Figure 3); (C) incorporation of APCs-HUVECs coculture in sodium alginate/Pluronic F127 gel (AG/PL); (D) hydrogel patterning
on the seeded scaffold for the final assembling of the Hybrid scaffold. (E,G) show highly magnified fields of control (no cells) (E) 20mM (F) and 100mM (G)
crosslinked gel; (E) shows the absence of unspecific stain in the gel without cells; (F,G) show the living cells stained with calcein (Green) while dead cells are stained
with EthD-III (red); (H) Fluorescent microscopy image of the structure of the bioprinted structure in the shape of a 10 × 10mm grid; Dotted square shows the
magnified filed for (G); (I) Picture of the 10 × 10mm bioprinted grid; (J) Bar graph of cell viability of APCs and HUVECs loaded into the AG/PL gel and assessed after
the exposure to different concentration of CaCl2. (K) Fluorescence image of the bioprinted structure of the final pattern for the hybrid Scaffold composition; (L) SEM
picture of AG/PL gel printed onto the scaffold; (M,N) Representative images of the maintained pattern of the co-culture in the AG/PL gel extruded onto scaffold, after
5 days of incubation. APCs stained with Dil (red), HUVECs with DiO (green) and nuclei of both cell type with DAPI (blue). (M) poly(ε-caprolactone) with gelatin
nanofibers coated with bioprinted sodium alginate/Pluronic F127 gel (PCL-GL + AG/PL) loaded with HUVECs + APCs; (N) polylactic-co-glycolic acid with gelatin
nanofibers coated with bioprinted sodium alginate/Pluronic F127 gel (PLGA-GL + AG/PL) loaded with HUVECs + APCs.
morphology. This patterned scaffold prototype was then used in
studies evaluating the potential of vascular engineering in a limb
ischemia model.
Perivascular Implantation of Cellularized
Scaffolds Improves Collateralization and
Accelerates Blood Flow Recovery
The revascularization capacity of the hybrid scaffolds was tested
in a murine model of LI. Figures 7A,B shows the schematic
approach of implantation and the anatomical site of LI induction.
Five groups were studied: the control group did not receive any
treatment, while the experimental groups were implanted with
PLGA-GL + AG/PL or PCL-GL + AG/PL, with or without
APCs/HUVECs. Analysis of blood flow recovery in the ischemic
leg (normalized to contralateral side) showed that all groups
reached a similar plateau (Figure 7C). However, calculation of
the time necessary to reach the maximum recovery showed that
the group implanted with cellularized PLGA-AG/PL recovered
faster as compared with vehicle (11 vs. 18 days, respectively, P
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FIGURE 7 | Outcomes of the in vivo implantation study. (A,B) Schematic representation (A) and photograph captured with optical microscopy of hybrid scaffold
implantation (B); (C) Time course of blood flow recovery expressed as the ratio of ischemic and contralateral limb; (N = 9–10 per group); (D) Bar graph showing the
velocity of blood flow recovery; data expressed as mean ± SE; N = 9–10 per group. Groups: (1) Vehicle: induction of unilateral limb ischemia (LI) without treatment; (2)
PCL: induction of LI and implantation of PCL-GL + AG/PL without cells; (3) PCL + CELLS: induction of LI and implantation of PLC-GL + AG/PL with cells; (4) PLGA:
induction of LI and implantation of PLGA-GL + AG/PL without cells; (5) PLGA + CELLS: induction of LI and implantation of PLGA-GL + AG/PL with cells. *p < 0.05
vs. vehicle.
TABLE 2 | Blood flow recovery.
Group n Mean 95% Cl
Vehicle 9 17.889 13.980–21.789
PCL 10 16.800 12.577–21.023
PCL + cells 10 13.600 8.472–18.728
PLGA 10 16.100 11.977–20.223
PLGA + cells 9 11.222 6.946–15.498
Table showing the time for the groups to reach maximum blood flow recovery. Values are
n of replicates per group, mean and the min and max values measured.
= 0.01). Likewise, the comparison between cellularized PLGA-
GL + AG/PL and acellular PLGA-GL + AG/PL was also close
to statistical significance (11 vs. 16 days, P = 0.07) (Figure 7D
and Table 2). The comparison between cellularized PCL-GL +
AG/PL and vehicle showed no significant difference in time to
recovery (14 vs. 18 days, P = 0.015).
Histological analysis of limb muscles revealed there was no
difference in capillary density between groups (Figures 8A,B).
Although the total number of arterioles was not different between
groups (Figure 8C), narrowing the analysis to the arterioles with
a diameter above 50µm, animals given cellularized PLGA-GL +
AG/PL scaffold showed a significant increase in this parameter
compared with the vehicle group (P < 0.05) or those given
cellularized PCL-GL + AG/PL scaffolds (P < 0.01) (Figure 8D).
The increased collateralization induced in the mice with PLGA-
GL + AG/PL scaffold may account for the accelerated perfusion
recovery observed in the same group (Figures 8E–I).
DISCUSSION
A variety of techniques for by-passing total femoral artery
occlusions and re-entering the true lumen in the distal artery
are available, but few have been tested in randomized trials. The
potentiation of collateralization represents a promising approach
to provide relief to the ischemic tissue. In the present study,
we attempted to achieve this goal through a tissue engineering
approach, encompassing several innovative processes. First, we
have set up a robust manufacture protocol for the hierarchical
production of a hybrid scaffold made of bioprinted PCL and
PLGA and electro-spun GL. Second, we verified the optimal
combination of synthetic materials and natural products (GL)
within the hybrid scaffold. Third, we gathered novel information
regarding the ability of the scaffold to direct seeded APCs toward
an angiogenic phenotype. Fourth, we succeeded in strengthening
the directionality of the bioengineered scaffold by covering the
initial layer of APCs with an additional patterned layer of AG/PL
gel encapsulating a co-culture of APCs and HUVECs. Fifth,
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FIGURE 8 | Angiogenesis assessment. (A) Representative fluorescent microscopy image of staining used to detect capillaries in the ischemic leg. (B) Bar graph
showing capillary density; (C,D) Bar graphs of arterioles counting in the perivascular area: (C) cumulative calculation of arterioles density; (D) calculation of arterioles
(Continued)
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FIGURE 8 | with diameter >50µm; (E–I) Representative images of perivascular area of the various groups: Vehicle group (E), PCL (F), PCL + CELLS (G), PLGA (H)
and finally PLGA + CELLS group (I). White arrows indicate the scaffold. Yellow arrows indicate arterioles. *P < 0.05 vs. vehicle. ##P < 0.01 vs. PCL-AG/PL without
cells; data expressed in mean ± SE; N = 6 per group. Groups: (1) Vehicle: induction of unilateral limb ischemia (LI) without treatment; (2) PCL: induction of LI and
implantation of PCL-GL + AG/PL without cells; (3) PCL + CELLS: induction of LI and implantation of PLC-GL + AG/PL with cells; (4) PLGA: induction of LI and
implantation of PLGA-GL + AG/PL without cells; (5) PLGA + CELLS: induction of LI and implantation of PLGA-GL+AG/PL with cells.
comparing two material formulations, with or without cells, in
a murine model of femoral artery occlusion, we documented
the superiority of cellularized PLGA-GL + AG/PL scaffolds in
stimulating large arterioles formation around the blocked artery
and encouraging faster blood flow recovery.
In a previous study, we set up an integrated manufacture
protocol using a computer-assisted writing system to generate
3D scaffolds with woodpile or channel patterns and electro-
spinning to deposit GL nanofibers onto the synthetic backbone.
The structure was then engineered with human APCs to
confer characteristics of a living material capable of supporting
revascularization after perivascular implantation (30). Here, the
successful approach was refined and extended, employing two
synthetic materials, PCL and PLGA, as a backbone substrate.
To achieve this goal, a piston-driven bioprinting system was
employed; with results demonstrating versatility of the technique
in achieving high-resolution and consistent geometry features
(line width and thickness) for both PCL and PLGA synthetic
matrices. We focused on a channel design because this patterning
is the most appropriate to encourage alignment of new arterioles
in limb muscles (30) and myocardial tissues (37–39).
Owing to differences in physical properties and
biocompatibility, the choice of synthetic material is crucial
for the success of medical scaffolds (40). Mechanical tests
confirmed the anisotropy of the channel structures made of
PCL and PLGA, confirming the more rigid behavior of the
latter in line with previous literature (41, 42). Moreover, PCL
maintained its stability over time, confirming the typical slow
degradation rate in wet conditions; while PLGA revealed a more
rapid decrease in both Young’s Modulus and strain at rupture,
which denotes greater fragility of the material.
Like ECM, scaffold micro- and nano-scale morphology (43)
and biochemical cues can impact cell behavior (44, 45). Previous
studies have explored the fabrication of composite scaffolds
combining different manufacturing systems with promising
results. This included rapid prototyping microfabrication
techniques, like 3D printing, fusion deposition modeling and
solid free form deposition, in combination with electrospinning
to generate composite scaffolds (46, 47). In another study,
electrohydrodynamic direct-jet was used to deposit microfibrous
bundles of collagen-I in order to improve cell adhesion (48).
The message from these studies was that composite scaffolds are
better than scaffolds made of a single material in supporting cell
viability. For this reason, and following on from our previous
study (30), we improved our scaffolds by applying a layer of GL
nanofibers using the electrospinning technique, so as to enhance
the adhesion features of the synthetic backbone.
APCs are considered progenitors of different mesenchymal
cell lines. Antigenic and expressional characterization of APCs
demonstrated that these cells maintained their pericyte-like
phenotype when seeded on 3D structures, as demonstrated by
the expression of several transcription factors associated with
stemness. This, together with the observed downregulation of
fibroblastic markers, suggests that the 3D environment does not
promote APC differentiation. Functional assays demonstrated
an overall excellent biocompatibility of the studied materials.
PCL- and PLGA-based scaffolds showed a similar capacity to
support the viability of seeded APCs. Nonetheless, a molecular
readout of apoptosis, the BAX/BLC2 ratio, was almost 2-fold
higher in APCs seeded on PCL compared with APCs on PLGA,
suggesting that the latter has superior biocompatibility. On the
other hand, the PCL-based scaffolds improved cell adherence,
which is compatible with PCL having mechanical properties
closer to natural soft tissues (40). Previous studies showed that
cell proliferation is greater on PCL than PLGA, due to the
difference in stiffness of the two materials (40, 49, 50). We could
not detect any difference in APC proliferation, possibly because
of the presence of nanofibrous GL, which acts like a biomimetic
substrate for growing cells.
Our previous transplantation study showed the complexity
of molecular pathways implicated in APC-induced activation of
neovascularization in a model of femoral artery occlusion (51).
Here, we show that the APC proangiogenic profile is remarkably
modified by the culture in a 3D environment, resulting in
the induction of angiogenic (VEGFA) and arteriogenic (FGF)
signaling. This expressional change could be advantageous
in conditions requiring the formation of collateral vessels.
It should be noted that VEGFA mRNA levels and VEGFA
secretion in conditioned media showed similar increases in both
cellularized 3D PLGA and PCL scaffolds compared with 2D
control counterparts (from 4 to 6-fold, respectively). Meanwhile,
ANGPT1 expression in conditioned media was downregulated
in the 3D transition of PCL but not of PLGA. ANGPT1 is an
oligomeric secreted glycoprotein that plays a key role in the
organization and maturation of newly formed vessels, promoting
the quiescence and structural integrity of adult vasculature (52).
A key advancement of this study is the use of a piston-
driven bioprinting system to extrude a cell-laden gel containing a
mixture of APCs and ECs onto the scaffold. Bioprinted AG/PL gel
had less line width resolutionwhen comparedwith the bioprinted
synthetic polymer (PCL and PLGA). Nevertheless, the method
was highly reproducible in depositing a series of parallel lines.
The AG/PL gel lines would ideally synergize with the geometry of
the PCL- and PLGA-GL channels in directing arterial collaterals
in a parallel direction to the occluded femoral artery.
In the present study, we used two vascular cell populations
to encourage collateralization, incorporating APCs in the initial
layers and APCs and ECs into the patterned AG/PL gel. The
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advantage of combinatory administration is highlighted by
previous successful studies using human MSCs and cardiac
tissue-derived stem cells (CSCs) in a pig model of MI; with the
combination showing superior results compared with a single cell
population (53). Similarly, we have previously demonstrated that
in vivo co-delivery of human CSCs and APCs reduced the infarct
size and promoted vascular proliferation in a murine myocardial
infarction model (10). One limitation of this study is the use
of HUVECs instead of arterial ECs. However, this was proof
of principle study, and specific EC populations could be used
according to the implantation site.
After arterial occlusion, tissue recovery occurs through
the opening of pre-existing collaterals and formation of
new perivascular arterioles. Moreover, hypoxia induces the
formation of new muscular capillaries. Results of hemodynamic
and histologic analyses indicate the superiority of PLGA
scaffolds in accelerating reperfusion and promoting the
perivascular formation of arterioles with a diameter above
50µm. Characteristics of the bio-engineered material and host
response to the implant were identified as major players in
regenerative processes activated by hybrid scaffolds.
The balance between mechanical stability and
biodegradability play key roles in the design of successful
therapies. Despite the PCL scaffolds having a better match
of mechanical properties with the target tissue, the rate of
degradation of the scaffold should be comparable to the growth
of natural tissue (54). Here PLGA was demonstrated to have
a much faster degradability, with a decay rate within our
window of observation of 21 days. PLGA, also reportedly causes
inflammation and robust angiogenesis (27), in contrast to the
absence of inflammation and poor vascularization observed
after the implantation of polyurethane and collagen-chitosan-
hydroxyapatite (55). In addition, both PCL- and PLGA-based
scaffold showed upregulation of pro-angiogenic factors, but the
secretion of ANGPT1 was downregulated only in PCL scaffolds,
possibly reflecting the lack of functional collateralization.
CONCLUSION
Results of the present study represent an important step
toward the clinical use of perivascular biomaterials for the
revascularization around occluded limb arteries. Patients
with diabetic vascular disease extending to regions below
the knee could take advantage of this technique. We used
xenogeneic human cells in immunocompetent mice to
confirm the therapeutic efficacy of APCs in the absence of
immunosuppression. This provides a scope for the use of
allogeneic APCs in clinical trials. Furthermore, we have already
upgraded the APC production using clinical-grade reagents, an
important step forward clinical translation. However, additional
improvements are necessary for scaling-up cell production and
for integrating scaffold manufacture and bioengineering into a
single process.
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